Compounding pharmacies producing semaglutide and tirzepatide face serious legal risks from FDA enforcement, patent claims, and state regulations despite surging demand.
3 years of explosive growthThe compounded GLP-1 market went from nearly nonexistent to a major industry in roughly three years — driven by drug shortages, lack of insurance coverage, and enormous patient demand.
What the researchers found
Compounding pharmacies and outsourcing facilities face significant legal risks from producing compounded semaglutide and tirzepatide. While drug shortages and lack of insurance coverage for weight-loss use created strong financial incentives, the regulatory framework creates substantial liability.
The review identifies multiple risk areas: FDA enforcement against compounders, patent and trademark infringement claims from brand manufacturers, state-level regulatory actions, and potential liability from adverse patient outcomes. The fact that weight loss prescribing typically falls outside federal healthcare programs reduces some kickback risks but doesn't eliminate the core compounding legality questions.
Why it matters
Compounded semaglutide became a multi-billion-dollar grey market practically overnight. Millions of patients turned to compounding pharmacies when branded Ozempic and Wegovy were in chronic shortage and insurance wouldn't cover weight-loss prescriptions. This review lays out the legal minefield that both compounders and prescribing physicians face — a reality check for an industry that grew faster than the regulatory framework could keep up.
The numbers in context
Focus period: ~3 years of explosive growth in compounded GLP-1 market · primarily semaglutide and tirzepatide · weight loss use typically not covered by insurance · legal risks span federal, state, and civil litigation domains
How the study worked
Legal review article examining the regulatory framework for compounding semaglutide and tirzepatide, including FDA regulations, patent law, state pharmacy board rules, and relevant case law. The authors review the history of compounding regulation and apply it to the specific context of GLP-1 weight loss drugs.
Who was studied
Not applicable — legal/regulatory review article, not a clinical study
What this study cannot tell us
This is a legal commentary, not empirical research — it describes risks and regulatory frameworks rather than measuring outcomes. The legal landscape is evolving rapidly and varies by jurisdiction. The article focuses primarily on semaglutide with broader applicability noted for tirzepatide. It provides a cursory overview, as the authors note, not comprehensive legal guidance.
How to read the evidence
Expert opinion: a legal review article providing regulatory analysis and risk assessment from legal professionals. It is not empirical research and does not generate clinical evidence, but offers authoritative analysis of the regulatory framework.
When this study was published
Published in 2025, this review captures the legal landscape during the peak of the compounded semaglutide controversy. Given how rapidly regulations are evolving, some specifics may already be outdated.
The bigger picture
The compounded GLP-1 market is one of the most consequential regulatory battles in modern pharmacy. On one side: brand manufacturers (Novo Nordisk, Eli Lilly) arguing their patents and FDA approvals should be protected. On the other: millions of patients and thousands of compounders arguing that drug shortages and price barriers justify compounding. This review captures the legal tensions at the heart of a debate that will shape how peptide drugs reach patients for years to come.
Questions still open
- Will FDA enforcement effectively shut down the compounded semaglutide market now that shortages have eased?
- How will courts balance patient access arguments against manufacturer patent rights in pending litigation?
- Could new legislation create a clearer regulatory pathway for compounding high-demand peptide drugs?
Common questions
Is it legal to compound semaglutide?
Why did compounded semaglutide become so popular?
Read the original research
Legal Challenges to Compounding Drugs for Weight Loss.
International journal of pharmaceutical compounding, 29(4), 267-278
Citation
Combs, Blinn E; Howard, Brad. (2025). Legal Challenges to Compounding Drugs for Weight Loss.. International journal of pharmaceutical compounding, 29(4), 267-278.